[HTML][HTML] Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL)
experienced poor outcomes with intensive chemotherapy. This mature analysis explores the …
experienced poor outcomes with intensive chemotherapy. This mature analysis explores the …
[HTML][HTML] S119: Combination of mini-hyper-CVD and inotuzumab (INO) followed by Blinatumomab (Blina) consolidation in patients with relapsed/refractory (R/R) acute …
Background: The prognosis of patients (pts) with R/R ALL is poor. InO and blina as single
agents improved the outcomes of pts with R/R disease. Encouraging results were seen with …
agents improved the outcomes of pts with R/R disease. Encouraging results were seen with …
Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory …
BACKGROUND The outcome of patients with relapsed/refractory (R/R) acute lymphoblastic
leukemia (ALL) is poor. The combination of inotuzumab with low‐intensity mini–hyper‐CVD …
leukemia (ALL) is poor. The combination of inotuzumab with low‐intensity mini–hyper‐CVD …
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia …
Background The outcomes of patients with relapsed or refractory (R‐R) acute lymphoblastic
leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single‐agent …
leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single‐agent …
[HTML][HTML] Sequential combination of low-intensity chemotherapy (mini-hyper-CVD) plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed …
Background: The combination of low intensity therapy with inotuzumab ozogamicin
improved survival compared to intensive chemotherapy and to single agent inotuzumab …
improved survival compared to intensive chemotherapy and to single agent inotuzumab …
A phase II study of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome …
Background: Inotuzumab ozogamicin (INO) and blinatumomab are superior to
chemotherapy for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) …
chemotherapy for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) …
[HTML][HTML] Updated results of a phase II study of reduced-intensity chemotherapy with mini-hyper-CVD in combination with inotuzumab ozogamicin, with or without …
Background: Inotuzumab ozogamicin (INO) and blinatumomab both improve survival in
relapsed or refractory acute lymphoblastic leukemia (ALL) compared to conventional …
relapsed or refractory acute lymphoblastic leukemia (ALL) compared to conventional …
[HTML][HTML] Updated results from a phase II study of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed …
Background: Inotuzumab ozogamicin (INO) and blinatumomab are effective in the treatment
relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve overall survival …
relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve overall survival …
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome …
Background The outcome of older patients with B-cell acute lymphocytic leukaemia is
inferior to that in younger patients due to the adverse disease biology and their inability to …
inferior to that in younger patients due to the adverse disease biology and their inability to …
Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome …
E Jabbour, F Ravandi, P Kebriaei, X Huang… - JAMA …, 2018 - jamanetwork.com
Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic
leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to …
leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to …